However, the current ESMO recommendations for molecular testing in NSCLC only recommend analysis of a dedicated panel of genes related to currently approved target therapies (EGFR, ROS1, ALK, KRAS, BRAF, RET, MET, HER2, and NTRK). This evidence concerns the gene KRAS and non-small cell lung carcinoma.